Novartis AG (NVS)
| Market Cap | 282.97B +29.7% |
| Revenue (ttm) | 56.58B +6.3% |
| Net Income | 13.53B +5.2% |
| EPS | 6.98 +9.5% |
| Shares Out | 1.91B |
| PE Ratio | 20.91 |
| Forward PE | 16.50 |
| Dividend | $3.08 (2.08%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 829,343 |
| Open | 150.12 |
| Previous Close | 149.77 |
| Day's Range | 147.81 - 150.33 |
| 52-Week Range | 106.71 - 170.46 |
| Beta | 0.49 |
| Analysts | Hold |
| Price Target | 144.00 (-2.76%) |
| Earnings Date | Apr 28, 2026 |
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $144.0, which is a decrease of -2.76% from the latest price.
News
Health Rounds: Common ADHD medicines help treat cancer-related fatigue
We also report on findings that help explain why the flu can be particularly dangerous for pregnant women and that open the door to potential future treatments.
Novartis breaks ground on radioligand therapy manufacturing site in Texas
Novartis (NVS) broke ground on its new 46,000 sq. ft radioligand therapy manufacturing site in Denton, Texas, the latest milestone in its broader $23B investment in U.S. manufacturing and research.
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
Basel, May 7, 2026 – Novartis, a leading global innovative medicines company, today broke ground on its new 46,000 sq. ft radioligand therapy (RLT) manufacturing site in Denton, Texas, the latest mile...
Novartis to cut 220 jobs as it closes German site
Swiss drugmaker Novartis said on Tuesday that it is set to cut around 220 jobs in Germany as part of the planned closure of a production site by the end of 2028.
Novartis announces plans to add new facility in Morrisville, North Carolina
Novartis (NVS) announced plans to add a new facility in Morrisville, North Carolina, focused on active pharmaceutical ingredient, API, manufacturing for solid dosage tablets, capsules and RNA therapeu...
UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies
Britain's largest drugmakers saw 2026 get off on a positive note, with AstraZeneca and GSK both reporting core earnings ahead of expectations on Wednesday The CEOs of a number of European pharma giant...
Novartis CEO warns of reality of Trump's drug pricing policy
Novartis' CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult situation” and the reality will soon catch up with both drugmakers and patients.
Novartis CEO warns of reality of Trump's drug pricing policy
Novartis' CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult situation” and the reality will soon catch up with both drugmakers and patients.
Novartis (NVS) CEO Warns Trump Drug Pricing Policy Could Hit Global Access as Earnings Slip
Novartis AG ($NVS) released its first-quarter earnings this morning and raised fresh concerns about U.S. drug pricing policy, with CEO Vas Narasimhan warning that the impact could soon hit both…
Novartis reports Q1 core EPS $1.99 vs. $2.28 last year
Reports Q1 net sales $13.11B vs. $13.23B last year. Commenting on Q1 2026 results, Vas Narasimhan, CEO of Novartis (NVS), said: “Novartis delivered a strong start to 2026 across our…
Novartis shares fall after weak Q1 hit by Entresto competition
Novartis reported first-quarter core operating profit and sales below market expectations, as generic competition for its top-selling heart drug Entresto weighed on results. Shares of the Swiss drugma...
Novartis CEO: We knew these first two quarters would be bumpy
Novartis CEO Vas Narasimhan discusses the company's first quarter earnings, which missed expectations amid increasing generic competition in the key U.S. market.
Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'
Novartis' CEO warned Tuesday that U.S. drug pricing policy under President Donald Trump poses a "very difficult situation."
European markets to open higher as Trump considers Iran peace proposal
European stocks are expected to open higher on Tuesday as investors assess the latest developments in the Iran war, and look ahead to earnings reports.
Novartis Q1 profit down on US generic erosion
Swiss drugmaker Novartis reported first-quarter core operating profit below market expectations on Tuesday, as generic competition for its top-selling heart drug Entresto weighed on sales.
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed
Ad hoc announcement pursuant to Art. 53 LR First quarter Net sales declined -5% (cc 1 , -1% USD), as growth drivers were more than offset by US generic erosion Continued strong performance from priori...
Pharma bets a little-known cholesterol will underpin its next blockbuster heart drugs
Novartis, Amgen and Eli Lilly are among the pharmaceutical companies developing drugs to lower levels of a particularly bad form of cholesterol called Lp(a) and potentially prevent heart attacks. Lp(a...
Novartis announces EC approved Rhapsido for CSU
Novartis (NVS) announced that the European Commission, EC, approved Rhapsido for chronic spontaneous urticaria, CSU, in adult patients with inadequate response to H1-antihistamine treatment. “Today’s ...
Novartis receives European Commission approval for Rhapsido skin disease drug
Novartis has received European Commission approval for its drug Rhapsido, an oral treatment for chronic spontaneous urticaria (CSU), the Swiss drugmaker said on Monday.
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
Basel, April 27, 2026 – Novartis announced today that the European Commission (EC) approved Rhapsido® (remibrutinib) for chronic spontaneous urticaria (CSU) in adult patients with inadequate response ...
Novartis announces CHMP of EMA adopted positive opinion for Itvisma
Novartis (NVS) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has adopted a positive opinion recommending marketing authorization for I...
Novartis announces prequalification for Coartem Baby by WHO
Novartis (NVS) announced that the World Health Organization, or WHO, has prequalified Coartem Baby, the first and only antimalarial developed specifically for newborns and young infants weighing from ...
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
East Hanover, April 24, 2026 – Novartis today announced that the World Health Organization (WHO) has prequalified Coartem® (artemether-lumefantrine) Baby, the first and only antimalarial developed spe...
Better Pharma Dividend Stock: Novartis vs. Merck
Merck's outlook is bright despite challenges to its core franchises. Novartis is performing well despite a recent major patent cliff.
Instem Taps ex-Novartis Head of Emerging Technologies to Put Science Behind Practical AI and NAMs
BOSTON--(BUSINESS WIRE)--Instem announces the appointment of Szczepan Baran, VMD, MS, as Chief Scientific Officer to lead Instem's scientific and AI strategy.